Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs
Unresectable nodular and diffuse hepatocellular carcinoma (HCC) have a poor prognosis with limited treatment options. Systemic traditional chemotherapy has been only rarely reported, with unsatisfactory results. The aim of this prospective, non-randomized, non-blinded, single center clinical trial w...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-05-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/5/1272 |
| _version_ | 1797567657079209984 |
|---|---|
| author | Laura Marconato Silvia Sabattini Giorgia Marisi Federica Rossi Vito Ferdinando Leone Andrea Casadei-Gardini |
| author_facet | Laura Marconato Silvia Sabattini Giorgia Marisi Federica Rossi Vito Ferdinando Leone Andrea Casadei-Gardini |
| author_sort | Laura Marconato |
| collection | DOAJ |
| description | Unresectable nodular and diffuse hepatocellular carcinoma (HCC) have a poor prognosis with limited treatment options. Systemic traditional chemotherapy has been only rarely reported, with unsatisfactory results. The aim of this prospective, non-randomized, non-blinded, single center clinical trial was to investigate safety profile, objective response rate, time to progression and overall survival of sorafenib in comparison with metronomic chemotherapy (MC) consisting of thalidomide, piroxicam and cyclophosphamide in dogs with advanced, unresectable HCC. Between December 2011 and June 2017, 13 dogs were enrolled: seven received sorafenib, and six were treated with MC. Median time to progression was 363 days (95% CI, 191–535) in dogs treated with sorafenib versus 27 days (95% CI, 0–68) in dogs treated with MC (<i>p</i> = 0.044). Median overall survival was 361 days (95% CI, 0–909) in dogs receiving sorafenib, while 32 days (95% CI, 0–235) in those receiving MC (<i>p</i> = 0.079). Sorafenib seems to be a good candidate for the treatment of dogs with advanced HCC, due to a benefit in disease control and an acceptable safety profile, offering a good basis on which new randomized prospective clinical trials should be undertaken to compare the efficacy and drawback of sorafenib versus MC or traditional chemotherapy. |
| first_indexed | 2024-03-10T19:45:24Z |
| format | Article |
| id | doaj.art-186d28ee01c4457c80df37b99b04a5c8 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T19:45:24Z |
| publishDate | 2020-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-186d28ee01c4457c80df37b99b04a5c82023-11-20T00:49:19ZengMDPI AGCancers2072-66942020-05-01125127210.3390/cancers12051272Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in DogsLaura Marconato0Silvia Sabattini1Giorgia Marisi2Federica Rossi3Vito Ferdinando Leone4Andrea Casadei-Gardini5Department of Veterinary Medical Sciences, University of Bologna, via Tolara di Sopra 50, Ozzano dell’Emilia, 40064 Bologna, ItalyDepartment of Veterinary Medical Sciences, University of Bologna, via Tolara di Sopra 50, Ozzano dell’Emilia, 40064 Bologna, ItalyBiosciences Laboratory, Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Via Piero Maroncelli 40, Meldola, 47014 Forlì-Cesena, ItalyCentro Oncologico Veterinario, via San Lorenzo 1-4, Sasso Marconi, 40037 Bologna, ItalyCentro Oncologico Veterinario, via San Lorenzo 1-4, Sasso Marconi, 40037 Bologna, ItalyDivision of Oncology, Department of Oncology and Hematology, University Hospital Modena, 41124 Modena, ItalyUnresectable nodular and diffuse hepatocellular carcinoma (HCC) have a poor prognosis with limited treatment options. Systemic traditional chemotherapy has been only rarely reported, with unsatisfactory results. The aim of this prospective, non-randomized, non-blinded, single center clinical trial was to investigate safety profile, objective response rate, time to progression and overall survival of sorafenib in comparison with metronomic chemotherapy (MC) consisting of thalidomide, piroxicam and cyclophosphamide in dogs with advanced, unresectable HCC. Between December 2011 and June 2017, 13 dogs were enrolled: seven received sorafenib, and six were treated with MC. Median time to progression was 363 days (95% CI, 191–535) in dogs treated with sorafenib versus 27 days (95% CI, 0–68) in dogs treated with MC (<i>p</i> = 0.044). Median overall survival was 361 days (95% CI, 0–909) in dogs receiving sorafenib, while 32 days (95% CI, 0–235) in those receiving MC (<i>p</i> = 0.079). Sorafenib seems to be a good candidate for the treatment of dogs with advanced HCC, due to a benefit in disease control and an acceptable safety profile, offering a good basis on which new randomized prospective clinical trials should be undertaken to compare the efficacy and drawback of sorafenib versus MC or traditional chemotherapy.https://www.mdpi.com/2072-6694/12/5/1272doghepatocellular carcinomametronomic therapyoutcomesorafenibtoxicity |
| spellingShingle | Laura Marconato Silvia Sabattini Giorgia Marisi Federica Rossi Vito Ferdinando Leone Andrea Casadei-Gardini Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs Cancers dog hepatocellular carcinoma metronomic therapy outcome sorafenib toxicity |
| title | Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs |
| title_full | Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs |
| title_fullStr | Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs |
| title_full_unstemmed | Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs |
| title_short | Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs |
| title_sort | sorafenib for the treatment of unresectable hepatocellular carcinoma preliminary toxicity and activity data in dogs |
| topic | dog hepatocellular carcinoma metronomic therapy outcome sorafenib toxicity |
| url | https://www.mdpi.com/2072-6694/12/5/1272 |
| work_keys_str_mv | AT lauramarconato sorafenibforthetreatmentofunresectablehepatocellularcarcinomapreliminarytoxicityandactivitydataindogs AT silviasabattini sorafenibforthetreatmentofunresectablehepatocellularcarcinomapreliminarytoxicityandactivitydataindogs AT giorgiamarisi sorafenibforthetreatmentofunresectablehepatocellularcarcinomapreliminarytoxicityandactivitydataindogs AT federicarossi sorafenibforthetreatmentofunresectablehepatocellularcarcinomapreliminarytoxicityandactivitydataindogs AT vitoferdinandoleone sorafenibforthetreatmentofunresectablehepatocellularcarcinomapreliminarytoxicityandactivitydataindogs AT andreacasadeigardini sorafenibforthetreatmentofunresectablehepatocellularcarcinomapreliminarytoxicityandactivitydataindogs |